Incyte

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. 

CEO
William J. Meury
CEOWilliam J. Meury
Employees
2,844
Employees2,844
Headquarters
Wilmington, Delaware
HeadquartersWilmington, Delaware
Founded
1991
Founded1991
Employees
2,844
Employees2,844

INCY Key Statistics

Market cap
19.47B
Market cap19.47B
Price-Earnings ratio
15.26
Price-Earnings ratio15.26
Dividend yield
Dividend yield
Average volume
1.28M
Average volume1.28M
High today
$97.90
High today$97.90
Low today
$92.49
Low today$92.49
Open price
$96.60
Open price$96.60
Volume
1.53M
Volume1.53M
52 Week high
$112.29
52 Week high$112.29
52 Week low
$56.13
52 Week low$56.13

Stock Snapshot

With a market cap of 19.47B, Incyte(INCY) trades at $92.49. The stock has a price-to-earnings ratio of 15.26.

On 2026-04-20, Incyte(INCY) stock moved within a range of $92.49 to $97.90. With shares now at $92.49, the stock is trading 0.0% above its intraday low and -5.5% below the session's peak.

Trading volume for Incyte(INCY) stock has reached 1.53M, versus its average volume of 1.28M.

Over the past 52 weeks, Incyte(INCY) stock has traded between a high of $112.29 and a low of $56.13.

Over the past 52 weeks, Incyte(INCY) stock has traded between a high of $112.29 and a low of $56.13.

INCY News

Simply Wall St 3d
Is It Too Late To Consider Incyte After Its 63.8% One Year Rally?

If you are wondering whether Incyte’s current share price lines up with its underlying worth, the key question is how the market is valuing its future cash flow...

Is It Too Late To Consider Incyte After Its 63.8% One Year Rally?
Simply Wall St 5d
Assessing Incyte Valuation After New Adagene Collaboration In Colorectal Cancer

Advertisement Clinical collaboration puts fresh focus on Incyte stock Incyte (INCY) is back on investor radars after Adagene announced a clinical collaboratio...

Assessing Incyte Valuation After New Adagene Collaboration In Colorectal Cancer

Analyst ratings

52%

of 29 ratings
Buy
37.9%
Hold
51.7%
Sell
10.3%

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.